Company
Headquarters: Epalinges, Switzerland
Employees: 6
€4.7 Million
EUR as of July 1, 2023
US$5.1 Million
| Company | Market Cap (USD) |
|---|---|
| Zoetis Inc. | $89.09 B |
| MERCK Kommanditgesellschaft auf Aktien | $67.64 B |
| Takeda Pharmaceutical Company Limited | $47.71 B |
| Haleon plc | $38.90 B |
| PPD, Inc. | $16.58 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Elanix Biotechnologies AG, a tissue regeneration company, develops and commercializes products for acute wound care, dermatological, and gynecological applications, and provides cell technology services. It also owns cell banks containing various quantities of cells. The company was founded in 1966 and is headquartered in Epalinges, Switzerland.
Top 1-year algo backtest: +298.72%
$10,000 in April 2023 would now be $39,872 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
El.En. SpA has the following listings and related stock indices.
Stock: FSX: ELN wb_incandescent